REGISTER
OCC 2026 | From Blood Pressure Control to Causal Treatment
Prof. Xiangqing Kong explains why hypertension remains difficult to control despite multiple drugs. He compares current therapy to symptom relief rather than cure, and proposes that future treatment should target root mechanisms, including central nervous system regulation and perirenal adipose tissue signaling.

In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts from China and Australia gather to discuss “Hypertension · Cornerstone Chapter — From Blood Pressure Management to Root-Cause Innovation”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-hosted by Prof. Dongying Zhang, The First Affiliated Hospital of Chongqing Medical University. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Xiangqing Kong, The First Affiliated Hospital with Nanjing Medical University; and Prof. Alberto P. Avolio, Macquarie University, Australia.

The roundtable focuses on how hypertension care may evolve from numerical blood pressure control toward mechanism-based and precision-oriented management. The experts discuss the limitations of lifelong medication, the low global control rate of hypertension, central nervous system regulation, perirenal adipose tissue as a potential therapeutic target, arterial stiffness and hemodynamic mechanisms, cuffless and wearable blood pressure monitoring, clinical validation standards, and the future role of Chinese innovation in reshaping global hypertension treatment.

In this segment, Prof. Xiangqing Kong discusses why hypertension control remains challenging despite the availability of multiple antihypertensive drugs. He compares current treatment to fever-reducing medicine — useful for symptom control, but not a true cure — and suggests that future hypertension therapy should move toward an “antibiotic-like” approach that targets the root cause of elevated blood pressure.

Prof. Kong shares his hypothesis that hypertension may be linked to an upregulated blood pressure set point within the central nervous system, potentially triggered by signals from perirenal adipose tissue through afferent nerve pathways. Prof. Dongying Zhang adds that this mechanism may apply to specific patient subgroups rather than all patients, highlighting the need for further clinical validation and precision-oriented treatment.

0
0
Loading